Ahead of Bio 2024, we caught up with Matt Cokely, global technical consultant strategic leader, and Helen Gates, marketing director, at Ecolab Life Sciences to find out what the company is planning for the event and how it is navigating current challenges...
Celularity, a biotech company specializing in placental-derived allogeneic cell therapies, will be showcasing data at the upcoming ASGCT Annual Meeting, showcasing the potential of their off-the-shelf natural killer (NK) cells to combat age-related diseases....
Colleen Acosta is CEO of Freya Biosciences which is a trans-Atlantic clinical-stage biotech company pioneering microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of women’s reproductive system conditions and we were...
CDMO Wheeler Bio, Inc. has welcomed Charles River’s flexible biologics testing lab, RightSource, to its Oklahoma City drug substance manufacturing site.
iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.
Switzerland headquartered Lonza said it is expanding its early development services (EDS) to North America, opening a new laboratory in Cambridge, Massachusetts (US).
The industry had over 50 new molecular entities (NMEs) approved by the US Food and Drug Administration (FDA) in both 2020 and 2021, up from an annual total of 29 a decade ago.
Unveiled at the 2022 BIO International Convention, the group's third annual diversity, equity, and inclusion report spotlights improvements both made and needed.
Capital investments in Swiss biotech companies reached CHF 3.33bn ($3.53bn) in 2021; while R&D investments increased to a record-high CHF 2.56bn ($2.71bn).
Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies...
Australian biotech researchers and entrepreneurs are being encouraged to apply for funding from the country’s first national biotech incubator, CUREator.
Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.
